193 related articles for article (PubMed ID: 12120178)
1. Pegylated interferons.
Baker DE
Rev Gastroenterol Disord; 2001; 1(2):87-99. PubMed ID: 12120178
[TBL] [Abstract][Full Text] [Related]
2. Pegylated interferon plus ribavirin for the treatment of chronic hepatitis C.
Baker DE
Rev Gastroenterol Disord; 2003; 3(2):93-109. PubMed ID: 12776006
[TBL] [Abstract][Full Text] [Related]
3. Spotlight on peginterferon-alpha-2a (40KD) in chronic hepatitis C.
Perry CM; Jarvis B
BioDrugs; 2002; 16(3):213-7. PubMed ID: 12102649
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of peginterferons.
Zeuzem S; Welsch C; Herrmann E
Semin Liver Dis; 2003; 23 Suppl 1():23-8. PubMed ID: 12934165
[TBL] [Abstract][Full Text] [Related]
5. A randomised trial to compare the pharmacokinetic, pharmacodynamic, and antiviral effects of peginterferon alfa-2b and peginterferon alfa-2a in patients with chronic hepatitis C (COMPARE).
Silva M; Poo J; Wagner F; Jackson M; Cutler D; Grace M; Bordens R; Cullen C; Harvey J; Laughlin M
J Hepatol; 2006 Aug; 45(2):204-13. PubMed ID: 16780997
[TBL] [Abstract][Full Text] [Related]
6. Incidence of neutropenia and infections during combination treatment of chronic hepatitis C with pegylated interferon alfa-2a or alfa-2b plus ribavirin.
Antonini MG; Babudieri S; Maida I; Baiguera C; Zanini B; Fenu L; Dettori G; Manno D; Mura MS; Carosi G; Puoti M
Infection; 2008 Jun; 36(3):250-5. PubMed ID: 18458815
[TBL] [Abstract][Full Text] [Related]
7. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.
Fried MW; Shiffman ML; Reddy KR; Smith C; Marinos G; Gonçales FL; Häussinger D; Diago M; Carosi G; Dhumeaux D; Craxi A; Lin A; Hoffman J; Yu J
N Engl J Med; 2002 Sep; 347(13):975-82. PubMed ID: 12324553
[TBL] [Abstract][Full Text] [Related]
8. Comparison of peginterferon pharmacokinetic and pharmacodynamic profiles.
Bruno R; Sacchi P; Cima S; Maiocchi L; Novati S; Filice G; Fagiuoli S
J Viral Hepat; 2012 Jan; 19 Suppl 1():33-6. PubMed ID: 22233411
[TBL] [Abstract][Full Text] [Related]
9. Treatment of chronic hepatitis C infection with peginterferons plus ribavirin.
Fried MW; Hadziyannis SJ
Semin Liver Dis; 2004; 24 Suppl 2():47-54. PubMed ID: 15346246
[TBL] [Abstract][Full Text] [Related]
10. Pegylated interferons for chronic hepatitis C virus infection: an indirect analysis of randomized trials.
Chou R; Carson S; Chan BK
J Viral Hepat; 2008 Aug; 15(8):551-70. PubMed ID: 18482285
[TBL] [Abstract][Full Text] [Related]
11. Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group.
Glue P; Fang JW; Rouzier-Panis R; Raffanel C; Sabo R; Gupta SK; Salfi M; Jacobs S
Clin Pharmacol Ther; 2000 Nov; 68(5):556-67. PubMed ID: 11103758
[TBL] [Abstract][Full Text] [Related]
12. Pegylated interferon: new preparation. Chronic hepatitis C: advantageous for some patients, but more data needed.
Prescrire Int; 2003 Dec; 12(68):206-10. PubMed ID: 14986684
[TBL] [Abstract][Full Text] [Related]
13. Hepatitis C virus therapy to date.
Foster G; Mathurin P
Antivir Ther; 2008; 13 Suppl 1():3-8. PubMed ID: 18432157
[TBL] [Abstract][Full Text] [Related]
14. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis.
Heathcote EJ; Shiffman ML; Cooksley WG; Dusheiko GM; Lee SS; Balart L; Reindollar R; Reddy RK; Wright TL; Lin A; Hoffman J; De Pamphilis J
N Engl J Med; 2000 Dec; 343(23):1673-80. PubMed ID: 11106716
[TBL] [Abstract][Full Text] [Related]
15. Peginterferon alfa-2a/ribavirin in hepatitis C virus patients nontolerant or nonresponsive to peginterferon alfa-2b/ribavirin.
Rustgi VK; Esposito S; Hamzeh FM; Shiffman ML
Aliment Pharmacol Ther; 2008 Mar; 27(5):433-40. PubMed ID: 18081737
[TBL] [Abstract][Full Text] [Related]
16. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients.
Torriani FJ; Rodriguez-Torres M; Rockstroh JK; Lissen E; Gonzalez-García J; Lazzarin A; Carosi G; Sasadeusz J; Katlama C; Montaner J; Sette H; Passe S; De Pamphilis J; Duff F; Schrenk UM; Dieterich DT;
N Engl J Med; 2004 Jul; 351(5):438-50. PubMed ID: 15282351
[TBL] [Abstract][Full Text] [Related]
17. Peginterferon alfa-2a in patients with chronic hepatitis C.
Zeuzem S; Feinman SV; Rasenack J; Heathcote EJ; Lai MY; Gane E; O'Grady J; Reichen J; Diago M; Lin A; Hoffman J; Brunda MJ
N Engl J Med; 2000 Dec; 343(23):1666-72. PubMed ID: 11106715
[TBL] [Abstract][Full Text] [Related]
18. Characteristics of hepatitis C treatment with pegylated interferons and ribavirin.
Jiménez-Méndez R; Castañeda-Hernández G
Ann Hepatol; 2010; 9 Suppl():61-4. PubMed ID: 20713998
[TBL] [Abstract][Full Text] [Related]
19. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial.
Carrat F; Bani-Sadr F; Pol S; Rosenthal E; Lunel-Fabiani F; Benzekri A; Morand P; Goujard C; Pialoux G; Piroth L; Salmon-Céron D; Degott C; Cacoub P; Perronne C;
JAMA; 2004 Dec; 292(23):2839-48. PubMed ID: 15598915
[TBL] [Abstract][Full Text] [Related]
20. Peginterferon alfa-2a: a review of approved and investigational uses.
Matthews SJ; McCoy C
Clin Ther; 2004 Jul; 26(7):991-1025. PubMed ID: 15336466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
